BSE Live
Jan 29, 16:01Prev. Close
1140.15
Open Price
1135.80
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Jan 29, 15:59Prev. Close
1139.90
Open Price
1140.40
Bid Price (Qty.)
1150.60 (541)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of Aurobindo Pharma (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 3,743.04 | 3,091.35 | 3,241.18 | 3,060.84 | 2,744.30 | |
| Net CashFlow From Operating Activities | 4,381.28 | 1,650.97 | 1,954.52 | 3,278.58 | 1,419.76 | |
| Net Cash Used In Investing Activities | -1,567.64 | -2,902.59 | -1,926.59 | -1,787.04 | -1,445.21 | |
| Net Cash Used From Financing Activities | -1,947.18 | 1,919.06 | 864.15 | -1,915.26 | 365.44 | |
| Foreign Exchange Gains / Losses | 4.78 | -1.80 | -0.17 | -0.14 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 871.24 | 665.64 | 891.91 | -423.86 | 339.99 | |
| Cash And Cash Equivalents Begin of Year | 1,875.58 | 1,209.94 | 318.03 | 743.49 | 403.81 | |
| Cash And Cash Equivalents End Of Year | 2,746.82 | 1,875.58 | 1,209.94 | 319.63 | 743.80 |
07.01.2026
02.01.2026
19.12.2025
15.12.2025
12.11.2025
Aurobindo Pharm Standalone September 2025 Net Sales at Rs 2,789.72 crore, down 1.23% Y-o-Y
07.11.2025
Aurobindo Pharm Consolidated September 2025 Net Sales at Rs 8,285.70 crore, up 6.28% Y-o-Y
12.08.2025
Aurobindo Pharm Consolidated June 2025 Net Sales at Rs 7,868.14 crore, up 3.98% Y-o-Y
05.08.2025
Aurobindo Pharm Standalone June 2025 Net Sales at Rs 2,848.17 crore, up 15.78% Y-o-Y
14.07.2023
Cipla Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
14.07.2023
Aurobindo Pharma Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
13.07.2022
Aurobindo Q1 PAT may dip 26.1% YoY to Rs 568.8 cr: ICICI Direct
08.07.2022
Aurobindo Pharma Q1 PAT may dip 20.7% YoY to Rs 610.7 cr: Prabhudas Lilladher
11.02.2019
Analysts remain positive on Aurobindo Pharma, expect stock to return 8-30% after Q3 earnings
25.08.2018
Pharma Q1 review: Brokerages say performance a mixed bag, but are upbeat on domestic biz
10.08.2017
When Rakesh Jhunjhunwala grilled Aurobindo Pharma top brass after muted Q1 results
24.08.2016
Aurobindo to see growth in H2; capacity constraints continue: PL